Details of the Drug

General Information of Drug (ID: DMJYCVW)

Drug Name
Warfarin
Synonyms
Brumolin; Choice; Coumadin; Coumafen; Coumafene; Coumaphen; Coumaphene; Coumarins; Coumefene; Dethmor; Dethnel; Kumader; Kumadu; Kumatox; Kypfarin; Maveran; Panwarfin; Prothromadin; RAX; Ratorex; Ratoxin; Ratron; Rattentraenke; Rattunal; Rodafarin; Rosex; Sofarin; Solfarin; Warfarat; Warfarina; Warfarine; Warfarinum; Warficide; Zoocoumarin; Arab Rat Death; Arab rat deth; Coumafene [French]; Dicusat E; Eastern states duocide; Fasco fascrat powder; Maag Rattentod Cum; Mouse pak; Ratron G; Rattenstreupulver Neu Schacht; Rattenstreupulver new schacht; Rodafarin C; Rodex blox; Sorexa plus; Temus W; Twin light rat away; Vampirinip II; Vampirinip iii; Warfarin Q; Warfarin plus; Warfarin plus [discontinued]; Zoocoumarin [Netherlands and USSR]; Zoocoumarin [Russian]; CBKinase1_000192; CBKinase1_012592; Latka 42; Latka 42 [Czech]; PS104_SUPELCO; WARF compound 42; Warf 10; Warf 42; Athrombine-K; CO-Rax; Choice (TN); Coumadin (TN); D-Con; Frass-Ratron; Jantoven (TN); Liqua-tox; Mar-Frin; Marevan (TN); Place-pax; Rac-Warfarin; Rat & mice bait; Rat-Gard; Rat-Kill; Rat-Mix; Rat-Ola; Rat-Trol; Ratten-Koederrohr; Ro-Deth; Rough & ready mouse mix; Tox-hid; Waran (TN); Warfarin (INN); Warfarin (and salts of); Warfarin [BSI:ISO]; Warfarin [INN:BAN]; Warfarin(R); Warfarina [INN-Spanish]; Warfarine [INN-French]; Warfarine [ISO-French]; Warfarinum [INN-Latin]; Cov-R-Tox; Martin's mar-frin; Rat-B-gon; Rat-a-way; Rats-no-more; Spray-trol brand roden-trol; Rat-o-cide #2; Warfarin titrated to an INR of 2.5-3.0; W.A.R.F. 42; (-)-Warfarin; (S)-Warfarin; 200 coumarin
Indication
Disease Entry ICD 11 Status REF
Atrial fibrillation BC81.3 Approved [1]
Deep vein thrombosis BD71 Approved [2]
Pulmonary hypertension BB01 Approved [2]
Thrombosis DB61-GB90 Application submitted [3]
Intracranial embolism 8B22.1 Investigative [2]
Venous thromboembolism BD72 Investigative [2]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticoagulants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 308.3
Logarithm of the Partition Coefficient (xlogp) 2.7
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 4 h [4]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
Bioavailability
93% of drug becomes completely available to its intended biological destination(s) [6]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.055 mL/min/kg [7]
Elimination
80% of the total dose is excreted in the urine with the remaining 20% appearing in the feces [8]
Half-life
The concentration or amount of drug in body reduced by one-half in 21 - 43 hours [7]
Metabolism
The drug is metabolized via the CYP2C8 with some contirbuting by CYP2C19 [8]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.54162 micromolar/kg/day [9]
Unbound Fraction
The unbound fraction of drug in plasma is 0.015% [7]
Vd
The volume of distribution (Vd) of drug is 0.14 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.018 mg/mL [5]
Chemical Identifiers
Formula
C19H16O4
IUPAC Name
4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one
Canonical SMILES
CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O
InChI
InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3
InChIKey
PJVWKTKQMONHTI-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
54678486
ChEBI ID
CHEBI:87732
CAS Number
81-81-2
DrugBank ID
DB00682
TTD ID
D0E3OF
VARIDT ID
DR00984
INTEDE ID
DR1717
ACDINA ID
D00736
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vitamin K epoxide reductase complex 1 (VKORC1) TTEUC8H VKOR1_HUMAN Inhibitor [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 2C9 (CYP2C9)
Main DME 		DE5IED8 CP2C9_HUMAN Substrate [13]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [14]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [15]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [15]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [16]
Sulfotransferase 1A1 (SULT1A1) DEYWLRK ST1A1_HUMAN Substrate [17]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Substrate [18]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Albumin (ALB) OTVMM513 ALBU_HUMAN Protein Interaction/Cellular Processes [19]
Alpha-1-acid glycoprotein 1 (ORM1) OTZKSBRE A1AG1_HUMAN Drug Response [20]
Antithrombin-III (SERPINC1) OTDFATG0 ANT3_HUMAN Gene/Protein Processing [21]
Apolipoprotein A-I (APOA1) OT5THARI APOA1_HUMAN Drug Response [22]
Apolipoprotein B-100 (APOB) OTH0UOCZ APOB_HUMAN Drug Response [23]
Apolipoprotein E (APOE) OTFOWL2H APOE_HUMAN Drug Response [24]
Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) OT0DH40W AL5AP_HUMAN Gene/Protein Processing [25]
Arylsulfatase L (ARSL) OTF1VTCR ARSL_HUMAN Gene/Protein Processing [26]
Aspartyl/asparaginyl beta-hydroxylase (ASPH) OT3KGDEE ASPH_HUMAN Drug Response [27]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Drug Response [28]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Warfarin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metreleptin DM1NOEK Moderate Decreased metabolism of Warfarin caused by Metreleptin mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [29]
Glibenclamide DM8JXPZ Moderate Increased plasma concentration of Warfarin and Glibenclamide due to competitive binding of plasma proteins. Acute diabete complication [5A2Y] [30]
Nateglinide DMLK2QH Moderate Decreased metabolism of Warfarin caused by Nateglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [31]
Glipizide DMZA5PQ Moderate Increased plasma concentration of Warfarin and Glipizide due to competitive binding of plasma proteins. Acute diabete complication [5A2Y] [30]
Arn-509 DMT81LZ Moderate Increased metabolism of Warfarin caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [32]
Emapalumab DMZG5WL Moderate Altered metabolism of Warfarin due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [33]
Metronidazole DMTIVEN Major Decreased metabolism of Warfarin caused by Metronidazole mediated inhibition of CYP450 enzyme. Amoebiasis [1A36] [34]
Siltuximab DMGEATB Moderate Altered metabolism of Warfarin due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [33]
Methylphenobarbital DMDSWAG Major Increased metabolism of Warfarin caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [35]
Posaconazole DMUL5EW Moderate Decreased metabolism of Warfarin caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [36]
Zileuton DMVRIC2 Moderate Decreased metabolism of Warfarin caused by Zileuton mediated inhibition of CYP450 enzyme. Asthma [CA23] [37]
Dupilumab DMOAD2Y Moderate Altered metabolism of Warfarin due to Dupilumab alters the formation of CYP450 enzymes. Atopic eczema [EA80] [38]
Oritavancin DM28D05 Moderate Decreased metabolism of Warfarin caused by Oritavancin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [39]
Tindamax DM3OWT4 Moderate Decreased metabolism of Warfarin caused by Tindamax mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [34]
Clarithromycin DM4M1SG Major Decreased metabolism of Warfarin caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [40]
Ticarcillin DM4ME02 Moderate Increased risk of bleeding by the combination of Warfarin and Ticarcillin. Bacterial infection [1A00-1C4Z] [41]
Sulfamethoxazole DMB08GE Major Increased plasma concentration of Warfarin and Sulfamethoxazole due to competitive binding of plasma proteins. Bacterial infection [1A00-1C4Z] [42]
Meticillin DMIKHN0 Moderate Increased risk of bleeding by the combination of Warfarin and Meticillin. Bacterial infection [1A00-1C4Z] [41]
Rabeprazole DMMZXIW Moderate Decreased metabolism of Warfarin caused by Rabeprazole mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [43]
Bacampicillin DMP54C7 Moderate Increased risk of bleeding by the combination of Warfarin and Bacampicillin. Bacterial infection [1A00-1C4Z] [41]
Oxacillin DMTAFY4 Moderate Increased risk of bleeding by the combination of Warfarin and Oxacillin. Bacterial infection [1A00-1C4Z] [41]
Cloxacillin DMUTL7O Moderate Increased risk of bleeding by the combination of Warfarin and Cloxacillin. Bacterial infection [1A00-1C4Z] [41]
Amoxicillin DMUYNEI Moderate Increased risk of bleeding by the combination of Warfarin and Amoxicillin. Bacterial infection [1A00-1C4Z] [41]
Troleandomycin DMUZNIG Major Decreased metabolism of Warfarin caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [40]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Warfarin caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [44]
Phytonadione DM8HDOL Moderate Antagonize the effect of Warfarin when combined with Phytonadione. Bleeding disorder [GA20-GA21] [45]
Esterified estrogens DM9KZDO Moderate Antagonize the effect of Warfarin when combined with Esterified estrogens. Breast cancer [2C60-2C6Y] [46]
Tucatinib DMBESUA Moderate Decreased metabolism of Warfarin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [47]
Alpelisib DMEXMYK Moderate Increased metabolism of Warfarin caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [48]
Quinestrol DMJ6H1Z Moderate Antagonize the effect of Warfarin when combined with Quinestrol. Breast cancer [2C60-2C6Y] [46]
Estradiol DMUNTE3 Moderate Antagonize the effect of Warfarin when combined with Estradiol. Breast cancer [2C60-2C6Y] [46]
Testolactone DMVY4GN Moderate Increased risk of bleeding by the combination of Warfarin and Testolactone. Breast cancer [2C60-2C6Y] [49]
Atorvastatin DMF28YC Minor Increased risk of bleeding by the combination of Warfarin and Atorvastatin. Cardiovascular disease [BA00-BE2Z] [50]
Fenofibric acid DMGO2MC Major Increased plasma concentration of Warfarin and Fenofibric acid due to competitive binding of plasma proteins. Cardiovascular disease [BA00-BE2Z] [51]
Chenodiol DMQ8JIK Moderate Increased risk of bleeding by the combination of Warfarin and Chenodiol. Cholelithiasis [DC11] [52]
Pentosan polysulfate DM2HRKE Moderate Increased risk of bleeding by the combination of Warfarin and Pentosan polysulfate. Chronic pain [MG30] [53]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Warfarin and Levomilnacipran. Chronic pain [MG30] [54]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Warfarin and Regorafenib. Colorectal cancer [2B91] [33]
Intedanib DMSTA36 Moderate Increased risk of bleeding by the combination of Warfarin and Intedanib. Colorectal cancer [2B91] [55]
Mestranol DMG3F94 Moderate Antagonize the effect of Warfarin when combined with Mestranol. Contraceptive management [QA21] [56]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Warfarin and Ardeparin. Coronary thrombosis [BA43] [57]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Warfarin caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [58]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Warfarin caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [32]
Ethanol DMDRQZU Moderate Increased risk of bleeding by the combination of Warfarin and Ethanol. Cystitis [GC00] [59]
MK-8228 DMOB58Q Moderate Increased metabolism of Warfarin caused by MK-8228 mediated induction of CYP450 enzyme. Cytomegaloviral disease [1D82] [60]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Warfarin and Danaparoid. Deep vein thrombosis [BD71] [57]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Warfarin and Rivaroxaban. Deep vein thrombosis [BD71] [61]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Warfarin and Sertraline. Depression [6A70-6A7Z] [54]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Warfarin and Vilazodone. Depression [6A70-6A7Z] [54]
Paroxetine DM5PVQE Moderate Increased risk of bleeding by the combination of Warfarin and Paroxetine. Depression [6A70-6A7Z] [54]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Warfarin and Vortioxetine. Depression [6A70-6A7Z] [54]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Warfarin and Milnacipran. Depression [6A70-6A7Z] [54]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Warfarin and Desvenlafaxine. Depression [6A70-6A7Z] [54]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Warfarin and Clomipramine. Depression [6A70-6A7Z] [54]
Heme DMGC287 Moderate Increased risk of bleeding by the combination of Warfarin and Heme. Discovery agent [N.A.] [62]
[3H]estrone-3-sulphate DMGPF0N Moderate Antagonize the effect of Warfarin when combined with [3H]estrone-3-sulphate. Discovery agent [N.A.] [56]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Warfarin and Apigenin. Discovery agent [N.A.] [63]
Benzylpenicillin DMS9503 Moderate Increased risk of bleeding by the combination of Warfarin and Benzylpenicillin. Discovery agent [N.A.] [41]
PMID28870136-Compound-49 DMTUC9E Moderate Increased risk of bleeding by the combination of Warfarin and PMID28870136-Compound-49. Discovery agent [N.A.] [64]
Primidone DM0WX6I Major Increased metabolism of Warfarin caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [65]
Felbamate DM1V5ZS Moderate Decreased metabolism of Warfarin caused by Felbamate mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [66]
Fosphenytoin DMOX3LB Moderate Increased risk of bleeding by the combination of Warfarin and Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [67]
Brivaracetam DMSEPK8 Minor Decreased metabolism of Warfarin caused by Brivaracetam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [33]
Rufinamide DMWE60C Moderate Increased metabolism of Warfarin caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [33]
Ethotoin DMXWOCP Moderate Increased risk of bleeding by the combination of Warfarin and Ethotoin. Epilepsy/seizure [8A61-8A6Z] [67]
Phenobarbital DMXZOCG Major Increased metabolism of Warfarin caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [65]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Warfarin caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [33]
Cannabidiol DM0659E Moderate Decreased metabolism of Warfarin caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [32]
Ethacrynic acid DM60QMR Moderate Increased plasma concentration of Warfarin and Ethacrynic acid due to competitive binding of plasma proteins. Essential hypertension [BA00] [32]
Suprofen DMKXJZ7 Moderate Increased risk of bleeding by the combination of Warfarin and Suprofen. Eye anterior segment structural developmental anomaly [LA11] [68]
Tazemetostat DMWP1BH Moderate Increased metabolism of Warfarin caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [69]
Itraconazole DMCR1MV Moderate Decreased metabolism of Warfarin caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [36]
Miconazole DMPMYE8 Major Decreased metabolism of Warfarin caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [70]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Warfarin caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [36]
Dexlansoprazole DM1DBV5 Moderate Decreased metabolism of Warfarin caused by Dexlansoprazole mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [43]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Warfarin and Avapritinib. Gastrointestinal stromal tumour [2B5B] [33]
Sulfinpyrazone DMEV954 Major Increased risk of bleeding by the combination of Warfarin and Sulfinpyrazone. Gout [FA25] [71]
Boceprevir DMBSHMF Moderate Antagonize the effect of Warfarin when combined with Boceprevir. Hepatitis virus infection [1E50-1E51] [72]
PSI-7977 DMLSUWZ Moderate Antagonize the effect of Warfarin when combined with PSI-7977. Hepatitis virus infection [1E50-1E51] [72]
Simeprevir DMLUA9D Moderate Antagonize the effect of Warfarin when combined with Simeprevir. Hepatitis virus infection [1E50-1E51] [72]
Telaprevir DMMRV29 Moderate Antagonize the effect of Warfarin when combined with Telaprevir. Hepatitis virus infection [1E50-1E51] [72]
Daclatasvir DMSFK9V Moderate Antagonize the effect of Warfarin when combined with Daclatasvir. Hepatitis virus infection [1E50-1E51] [72]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Warfarin caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [73]
Rifampin DMA8J1G Major Increased metabolism of Warfarin caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [74]
Rifapentine DMCHV4I Moderate Increased metabolism of Warfarin caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [75]
Delavirdine DM3NF5G Moderate Decreased metabolism of Warfarin caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [76]
Tipranavir DM8HJX6 Major Increased risk of bleeding by the combination of Warfarin and Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [77]
Etravirine DMGV8QU Moderate Decreased metabolism of Warfarin caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [78]
Atazanavir DMSYRBX Moderate Decreased metabolism of Warfarin caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [79]
Gemfibrozil DMD8Q3J Major Increased plasma concentration of Warfarin and Gemfibrozil due to competitive binding of plasma proteins. Hyper-lipoproteinaemia [5C80] [51]
Fenofibrate DMFKXDY Major Increased plasma concentration of Warfarin and Fenofibrate due to competitive binding of plasma proteins. Hyper-lipoproteinaemia [5C80] [51]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Warfarin and Dipyridamole. Hypertension [BA00-BA04] [80]
Conivaptan DM1V329 Minor Decreased metabolism of Warfarin caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [81]
Givosiran DM5PFIJ Moderate Decreased metabolism of Warfarin caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [82]
Amobarbital DM0GQ8N Major Increased metabolism of Warfarin caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [65]
Paraldehyde DMOC1BX Minor Increased metabolism of Warfarin caused by Paraldehyde mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [83]
Ceritinib DMB920Z Moderate Decreased metabolism of Warfarin caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [33]
PF-06463922 DMKM7EW Moderate Increased metabolism of Warfarin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [84]
Osimertinib DMRJLAT Moderate Increased metabolism of Warfarin caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [85]
Capmatinib DMYCXKL Moderate Decreased metabolism of Warfarin caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [86]
Selpercatinib DMZR15V Moderate Decreased metabolism of Warfarin caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [33]
Proguanil DMBL79I Moderate Decreased metabolism of Warfarin caused by Proguanil mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [87]
Sulphadoxine DMZI2UF Major Increased plasma concentration of Warfarin and Sulphadoxine due to competitive binding of plasma proteins. Malaria [1F40-1F45] [42]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Warfarin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [88]
Idelalisib DM602WT Moderate Decreased metabolism of Warfarin caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [89]
IPI-145 DMWA24P Moderate Decreased metabolism of Warfarin caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [90]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Warfarin and Acalabrutinib. Mature B-cell lymphoma [2A85] [91]
Blinatumomab DMGECIJ Moderate Decreased metabolism of Warfarin caused by Blinatumomab mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [92]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Warfarin and Ibrutinib. Mature B-cell lymphoma [2A85] [72]
Mercaptopurine DMTM2IK Moderate Antagonize the effect of Warfarin when combined with Mercaptopurine. Mature B-cell lymphoma [2A85] [93]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Warfarin and Ponatinib. Mature B-cell lymphoma [2A85] [94]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Warfarin caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [95]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Warfarin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [33]
Dienestrol DMBSXI0 Moderate Antagonize the effect of Warfarin when combined with Dienestrol. Menopausal disorder [GA30] [56]
Ethinyl estradiol DMODJ40 Moderate Antagonize the effect of Warfarin when combined with Ethinyl estradiol. Menopausal disorder [GA30] [56]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Warfarin due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [64]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Warfarin and Panobinostat. Multiple myeloma [2A83] [32]
Nilotinib DM7HXWT Moderate Decreased metabolism of Warfarin caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [96]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Warfarin and Dasatinib. Myeloproliferative neoplasm [2A20] [97]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Warfarin and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [53]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Warfarin and Prasugrel. Myocardial infarction [BA41-BA43] [33]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Warfarin and Vorapaxar. Myocardial infarction [BA41-BA43] [98]
Tirofiban DMQG17S Major Increased risk of bleeding by the combination of Warfarin and Tirofiban. Myocardial infarction [BA41-BA43] [99]
Modafinil DMYILBE Moderate Decreased metabolism of Warfarin caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [32]
Econazole DMFSWGH Moderate Decreased metabolism of Warfarin caused by Econazole mediated inhibition of CYP450 enzyme. Non-dermatophyte superficial dermatomycose [1F2D] [100]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Warfarin and Sibutramine. Obesity [5B80-5B81] [54]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Warfarin and Dexfenfluramine. Obesity [5B80-5B81] [54]
Orlistat DMRJSP8 Moderate Altered absorption of Warfarin caused by Orlistat. Obesity [5B80-5B81] [101]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Warfarin and Nepafenac. Osteoarthritis [FA00-FA05] [68]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Warfarin caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [102]
Carboplatin DMG281S Moderate Increased plasma concentration of Warfarin and Carboplatin due to competitive binding of plasma proteins. Ovarian cancer [2C73] [103]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Warfarin and MK-4827. Ovarian cancer [2C73] [33]
Aspirin DM672AH Major Increased risk of bleeding by the combination of Warfarin and Aspirin. Pain [MG30-MG3Z] [104]
Abametapir DM2RX0I Moderate Decreased metabolism of Warfarin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [105]
Esomeprazole DM7BN0X Moderate Decreased metabolism of Warfarin caused by Esomeprazole mediated inhibition of CYP450 enzyme. Peptic ulcer [DA61] [43]
Lefamulin DME6G97 Moderate Decreased metabolism of Warfarin caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [106]
Choline salicylate DM8P137 Moderate Increased risk of bleeding by the combination of Warfarin and Choline salicylate. Postoperative inflammation [1A00-CA43] [107]
Bromfenac DMKB79O Moderate Increased risk of bleeding by the combination of Warfarin and Bromfenac. Postoperative inflammation [1A00-CA43] [68]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Warfarin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [108]
Enzalutamide DMGL19D Moderate Increased metabolism of Warfarin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [32]
Estramustine DMWTAOI Moderate Antagonize the effect of Warfarin when combined with Estramustine. Prostate cancer [2C82] [46]
Bicalutamide DMZMSPF Minor Increased plasma concentration of Warfarin and Bicalutamide due to competitive binding of plasma proteins. Prostate cancer [2C82] [109]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Warfarin due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [33]
Ixekizumab DMXW92T Moderate Altered metabolism of Warfarin due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [33]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Warfarin and Epoprostenol. Pulmonary hypertension [BB01] [110]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Warfarin and Iloprost. Pulmonary hypertension [BB01] [110]
Salsalate DM13P4C Moderate Increased risk of bleeding by the combination of Warfarin and Salsalate. Rheumatoid arthritis [FA20] [107]
Tocilizumab DM7J6OR Moderate Altered metabolism of Warfarin due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [33]
Canakinumab DM8HLO5 Moderate Altered metabolism of Warfarin due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [33]
Rilonacept DMGLUQS Moderate Altered metabolism of Warfarin due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [33]
Flurbiprofen DMGN4BY Moderate Increased risk of bleeding by the combination of Warfarin and Flurbiprofen. Rheumatoid arthritis [FA20] [68]
Golimumab DMHZV7X Moderate Altered metabolism of Warfarin due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [33]
Sulfasalazine DMICA9H Major Decreased metabolism of Warfarin caused by Sulfasalazine mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [42]
Sarilumab DMOGNXY Moderate Altered metabolism of Warfarin due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [33]
Leflunomide DMR8ONJ Moderate Decreased metabolism of Warfarin caused by Leflunomide mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [111]
Salicyclic acid DM2F8XZ Moderate Increased risk of bleeding by the combination of Warfarin and Salicyclic acid. Seborrhoeic dermatitis [EA81] [112]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Warfarin caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [113]
Larotrectinib DM26CQR Moderate Decreased metabolism of Warfarin caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [32]
Armodafinil DMGB035 Moderate Decreased metabolism of Warfarin caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [32]
Etoposide DMNH3PG Moderate Increased plasma concentration of Warfarin and Etoposide due to competitive binding of plasma proteins. Solid tumour/cancer [2A00-2F9Z] [103]
Curcumin DMQPH29 Minor Increased risk of bleeding by the combination of Warfarin and Curcumin. Solid tumour/cancer [2A00-2F9Z] [114]
Pitolisant DM8RFNJ Moderate Increased metabolism of Warfarin caused by Pitolisant mediated induction of UGT. Somnolence [MG42] [33]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Warfarin caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [115]
Caplacizumab DMPUKA7 Major Increased risk of bleeding by the combination of Warfarin and Caplacizumab. Thrombocytopenia [3B64] [32]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Warfarin and Apixaban. Thrombosis [DB61-GB90] [33]
Cangrelor DM8JRH0 Major Increased risk of bleeding by the combination of Warfarin and Cangrelor. Thrombosis [DB61-GB90] [33]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Warfarin and Brilinta. Thrombosis [DB61-GB90] [33]
Clopidogrel DMOL54H Major Increased risk of bleeding by the combination of Warfarin and Clopidogrel. Thrombosis [DB61-GB90] [116]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Warfarin and Cabozantinib. Thyroid cancer [2D10] [117]
Azathioprine DMMZSXQ Moderate Antagonize the effect of Warfarin when combined with Azathioprine. Transplant rejection [NE84] [93]
Tolbutamide DM02AWV Moderate Increased plasma concentration of Warfarin and Tolbutamide due to competitive binding of plasma proteins. Type 2 diabetes mellitus [5A11] [30]
Lixisenatide DM0QJDC Minor Altered absorption of Warfarin due to GI dynamics variation caused by Lixisenatide. Type 2 diabetes mellitus [5A11] [32]
Albiglutide DM1JEGF Minor Altered absorption of Warfarin due to GI dynamics variation caused by Albiglutide. Type 2 diabetes mellitus [5A11] [118]
Mezlocillin DMY5JEP Moderate Increased risk of bleeding by the combination of Warfarin and Mezlocillin. Urinary tract infection [GC08] [41]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Warfarin and Betrixaban. Venous thromboembolism [BD72] [119]
Propafenone DMPIBJK Moderate Decreased metabolism of Warfarin caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [120]
Amiodarone DMUTEX3 Major Decreased metabolism of Warfarin caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [121]
⏷ Show the Full List of 177 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Aluminum hydroxide-glycine E00598 73415786 Other agent
D&C red no. 30 E00456 3000709 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
FD&C red no. 4 E00356 62542 Colorant
Hydrazine yellow E00409 164825 Colorant
Quinoline yellow WS E00309 24671 Colorant
Silotermo carmine G E00611 135487652 Colorant
Sunset yellow FCF E00255 17730 Colorant
Aluminum trihydroxide E00505 10176082 Alkalizing agent; Vaccine adjuvant
Barium oxide E00355 62392 Other agent
Barium sulfate E00289 24414 Binding agent; Colorant; Opacifying agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
D&C red no. 6 barium lake E00610 135462879 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hydroxypropyl cellulose E00632 Not Available Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
⏷ Show the Full List of 23 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Warfarin 3 mg tablet 3 mg Oral Tablet Oral
Warfarin 2 mg tablet 2 mg Oral Tablet Oral
Warfarin 2.5 mg tablet 2.5 mg Oral Tablet Oral
Warfarin 6 mg tablet 6 mg Oral Tablet Oral
Warfarin 7.5 mg tablet 7.5 mg Oral Tablet Oral
Warfarin 1 mg tablet 1 mg Oral Tablet Oral
Warfarin 4 mg tablet 4 mg Oral Tablet Oral
Warfarin 5 mg tablet 5 mg Oral Tablet Oral
Warfarin 10 mg tablet 10 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6853).
2 Warfarin FDA Label
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Warfarin DPD Monograph
5 BDDCS applied to over 900 drugs
6 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
7 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8 Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, Cuyckens F, Skee D, Murphy J, Sukbuntherng J, Mannens G: Absorption, metabolism, and excretion of oral (1)(4)C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97. doi: 10.1124/dmd.114.060061. Epub 2014 Dec 8.
9 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10 [Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036.
11 Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
12 Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin. Drug Metab Lett. 2010 Dec;4(4):213-9.
13 Pharmacogenomics of CYP2C9: functional and clinical considerations. J Pers Med. 2017 Dec 28;8(1).
14 Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chem Res Toxicol. 2009 Jul;22(7):1239-45.
15 Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metab Lett. 2012 Sep 1;6(3):157-64.
16 Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol. 1997;52(4):293-8.
17 Natural products isolated from Mexican medicinal plants: novel inhibitors of sulfotransferases, SULT1A1 and SULT2A1. Phytomedicine. 2001 Nov;8(6):481-8.
18 Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73(1):67-74.
19 The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem. 1999 Oct 8;274(41):29303-10. doi: 10.1074/jbc.274.41.29303.
20 Building individualized medicine: prevention of adverse reactions to warfarin therapy. J Pharmacol Exp Ther. 2007 Aug;322(2):427-34. doi: 10.1124/jpet.106.117952. Epub 2007 May 11.
21 Venous thrombosis, heparin-induced antithrombin III deficiency, and factor VIII. Lancet. 1977 Dec 10;2(8050):1231-2.
22 LRP1 and APOA1 Polymorphisms: Impact on Warfarin International Normalized Ratio-Related Phenotypes. J Cardiovasc Pharmacol. 2020 Jul;76(1):71-76. doi: 10.1097/FJC.0000000000000834.
23 APOB gene polymorphisms may affect the risk of minor or minimal bleeding complications in patients on warfarin maintaining therapeutic INR. Eur J Hum Genet. 2019 Oct;27(10):1542-1549. doi: 10.1038/s41431-019-0450-1. Epub 2019 Jun 11.
24 Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics. 2011 Mar;21(3):130-5. doi: 10.1097/FPC.0b013e3283436b86.
25 Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci U S A. 2006 May 23;103(21):8161-6. doi: 10.1073/pnas.0602414103. Epub 2006 May 12.
26 A cluster of sulfatase genes on Xp22.3: mutations in chondrodysplasia punctata (CDPX) and implications for warfarin embryopathy. Cell. 1995 Apr 7;81(1):15-25. doi: 10.1016/0092-8674(95)90367-4.
27 Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. Pharmacogenomics. 2016 Aug;17(13):1425-39. doi: 10.2217/pgs-2016-0061. Epub 2016 Aug 4.
28 Is there a role for MDR1, EPHX1 and protein Z gene variants in modulation of warfarin dosage? a study on a cohort of the Egyptian population. Mol Diagn Ther. 2014 Feb;18(1):73-83. doi: 10.1007/s40291-013-0055-2.
29 Product Information. Myalept (metreleptin). Bristol-Myers Squibb, Princeton, NJ.
30 Hansen JM, Christensen LK "Drug interactions with oral sulphonylurea hypoglycaemic drugs." Drugs 13 (1977): 24-34. [PMID: 401727]
31 Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
32 Cerner Multum, Inc. "Australian Product Information.".
33 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
34 Dean RP, Talbert RL "Bleeding associated with concurrent warfarin and metronidazole therapy." Drug Intell Clin Pharm 14 (1980): 864-6.
35 Antlitz AM, Tolentino M, Kosai MF "Effect of butabarbital on orally administered anticoagulants." Curr Ther Res Clin Exp 10 (1968): 70-3. [PMID: 4967727]
36 Brass C, Galgiani JN, Blaschke TF, et al "Disposition of ketoconazole, an oral antifungal, in humans." Antimicrob Agents Chemother 21 (1982): 151-8. [PMID: 6282204]
37 Awni WM, Hussein Z, Granneman GR, Patterson KJ, Dube LM, Cavanaugh JH "Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans." Clin Pharmacokinet 29(suppl 2 (1995): 67-76. [PMID: 8620673]
38 Product Information. Dupixent (dupilumab). sanofi-aventis, Bridgewater, NJ.
39 Product Information. Orbactiv (oritavancin). The Medicines Company, Parsippany, NJ.
40 Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E "The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy." Chest 126(3 Suppl) (2004): 204S-233S. [PMID: 15383473]
41 Alexander DP, Russo ME, Fohrman DE, Rothstein G "Nafcillin-induced platelet dysfunction and bleeding." Antimicrob Agents Chemother 23 (1983): 59-62. [PMID: 6830209]
42 Cook DE, Ponte CD "Suspected trimethoprim sulfamethoxazole induced hypoprothrombinemia." J Fam Pract 39 (1994): 589-91. [PMID: 7798864]
43 Ahmad S "Omeprazole-warfarin interaction." South Med J 84 (1991): 674-5. [PMID: 2035104]
44 Kolilekas L, Anagnostopoulos GK, Lampaditis I, Eleftheriadis I "Potential Interaction Between Telithromycin and Warfarin (September)." Ann Pharmacother 38 (2004): 1424-7. [PMID: 15280511]
45 Howard PA, Hannaman KN "Warfarin resistance linked to enteral nutrition products." J Am Diet Assoc 85 (1985): 713-5. [PMID: 3998343]
46 Koch-Weser J, Sellers EM "Drug interactions with coumarin anticoagulants (second of two parts)." N Engl J Med 285 (1971): 547-58. [PMID: 4397794]
47 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
48 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
49 de Oya JC, del Rio A, Noya M, Villanueva A "Decreased anticoagulant tolerance with oxymetholone in paroxysmal nocturnal haemoglobinuria." Lancet 2 (1971): 259. [PMID: 4104789]
50 Product Information. Lipitor (atorvastatin). Parke-Davis, Morris Plains, NJ.
51 Adkins JC, Faulds D "Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia." Drugs 54 (1997): 615-33. [PMID: 9339964]
52 Product Information. Chenodal (chenodeoxycholic acid). Manchester Pharmaceutical, Fort Collins, CO.
53 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
54 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
55 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
56 Notelovitz M "Oral contraception and coagulation." Clin Obstet Gynecol 28 (1985): 73-83. [PMID: 3987135]
57 Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
58 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
59 Breckenridge A "Clinical implications of enzyme induction." Basic Life Sci 6 (1975): 273-301. [PMID: 239673]
60 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
61 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
62 Product Information. Panhematin (hemin). Recordati Rare Diseases Inc, Lebanon, NJ.
63 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
64 Canadian Pharmacists Association.
65 Aggeler PM, O'Reilly RA "Effect of heptabarbital on the response to bishydroxycoumarin in man." J Lab Clin Med 74 (1969): 229-38. [PMID: 4184022]
66 Glue P, Banfield CR, Colucci RD, Perhach JL "Warfarin-felbamate interaction." Ann Pharmacother 28 (1994): 1412-3. [PMID: 7696739]
67 Hansen JM, Siersboek-Nielsen K, Skovsted L "Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man." Clin Pharmacol Ther 12 (1971): 539-43. [PMID: 5567804]
68 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
69 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
70 Ariyaratnam S, Thakker NS, Sloan P, Thornhill MH "Potentiation of warfarin anticoagulant activity by miconazole oral gel." BMJ 314 (1997): 349. [PMID: 9040331]
71 Bailey RR, Reddy J "Potentiation of warfarin action by sulphinpyrazone." Lancet 1 (1980): 254. [PMID: 6101699]
72 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
73 Eade NR, McLeod PJ, MacLeod SM "Potentiation of bishydroxycoumarin in dogs by isoniazid and paminosalicylic acid." Am Rev Respir Dis 103 (1971): 792-9. [PMID: 4103778]
74 Heimark LD, Gilbaldi M, Trager WF, et al "The mechanism of the warfarin-rifampin drug interaction in humans." Clin Pharmacol Ther 42 (1987): 388-94. [PMID: 3665337]
75 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
76 Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
77 Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
78 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
79 Hermans JJ, Thijssen HH "Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics." Br J Pharmacol 110 (1993): 482-90. [PMID: 8220911]
80 Donaldson DR, Sreeharan N, Crow MJ, Rajah SM "Assessment of the interaction of warfarin with aspirin and dipyridamole." Thromb Haemost 47 (1982): 77. [PMID: 6978549]
81 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
82 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
83 Product Information. Coumadin (warfarin). DuPont Pharmaceuticals, Wilmington, DE.
84 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
85 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
86 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
87 Product Information. Malarone (atovaquone-proguanil) Glaxo Wellcome, Research Triangle Pk, NC.
88 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
89 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
90 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
91 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
92 Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
93 Havrda DE, Rathbun S, Scheid D "A case report of warfarin resistance due to azathioprine and review of the literature." Pharmacotherpy 21 (2001): 355-7. [PMID: 11253860]
94 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
95 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
96 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
97 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
98 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
99 Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
100 Lang PG Jr, Leclercq AH "Increase in anticoagulant effect of warfarin in a patient using econazole cream." J Am Acad Dermatol 55(5 Suppl) (2006): S117-9. [PMID: 17052529]
101 MacWalter RS, Fraser HW, Armstrong KM "Orlistat enhances warfarin effect." Ann Pharmacother 37 (2003): 510-2. [PMID: 12659605]
102 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
103 Le AT, Hasson NK, Lum BL "Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy." Ann Pharmacother 31 (1997): 1006-8. [PMID: 9296241]
104 Barrow MV, Quick DT, Cunningham RW "Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases." Arch Intern Med 120 (1967): 620-4. [PMID: 6054600]
105 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
106 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
107 Richards JR, Garber D, Laurin EG, et al. Treatment of cocaine cardiovascular toxicity: a systematic review.?Clin Toxicol (Phila). 2016;54(5):345-364. [PMID: 26919414]
108 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
109 Product Information. Casodex (bicalutamide). Zeneca Pharmaceuticals, Wilmington, DE.
110 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
111 Chonlahan J, Halloran MA, Hammonds A "Leflunomide and warfarin interaction: case report and review of the literature." Pharmacotherapy 26 (2006): 868-71. [PMID: 16716139]
112 Fausa O "Salicylate-induced hypoprothrombinemia: a report of four cases." Acta Med Scand 188 (1970): 403-8. [PMID: 5490567]
113 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
114 Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
115 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
116 Anand S, Yusuf S, Xie C, et al. "Oral anticoagulant and antiplatelet therapy and peripheral arterial disease." N Engl J Med 357 (2007): 217-27. [PMID: 17634457]
117 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
118 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
119 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.
120 Kates RE, Yee YG, Kirsten EB "Interaction between warfarin and propafenone in healthy volunteer subjects." Clin Pharmacol Ther 42 (1987): 305-11. [PMID: 3621785]
121 Caraco Y, Chajek-Shaul T "The incidence and clinical significance of amiodarone and acenocoumarol interaction." Thromb Haemost 62 (1989): 906-8. [PMID: 2595664]